Martingale Asset Management L P Sells 28,489 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Martingale Asset Management L P reduced its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 95.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,478 shares of the medical research company's stock after selling 28,489 shares during the period. Martingale Asset Management L P's holdings in IQVIA were worth $290,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Norges Bank acquired a new position in IQVIA during the 4th quarter valued at $336,041,000. Raymond James Financial Inc. bought a new stake in shares of IQVIA in the fourth quarter valued at about $236,120,000. American Century Companies Inc. grew its position in IQVIA by 396.0% during the fourth quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company's stock worth $222,987,000 after buying an additional 905,960 shares in the last quarter. Invesco Ltd. increased its stake in IQVIA by 53.4% during the fourth quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock valued at $509,012,000 after acquiring an additional 902,226 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in shares of IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock worth $437,378,000 after acquiring an additional 583,396 shares during the period. 89.62% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently commented on IQV shares. JPMorgan Chase & Co. cut their target price on IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a research note on Tuesday, February 18th. BTIG Research cut shares of IQVIA from a "buy" rating to a "neutral" rating in a research note on Monday, February 3rd. Stifel Nicolaus decreased their target price on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. Royal Bank of Canada restated an "outperform" rating and set a $270.00 price target on shares of IQVIA in a research note on Monday, February 10th. Finally, Morgan Stanley upped their price objective on IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a research note on Tuesday, February 11th. Six investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, IQVIA currently has an average rating of "Moderate Buy" and a consensus target price of $241.50.

IQVIA Trading Down 3.2 %

Shares of IQV traded down $4.78 during trading hours on Friday, hitting $143.66. 3,302,597 shares of the stock traded hands, compared to its average volume of 1,403,069. The firm has a market capitalization of $25.33 billion, a PE ratio of 19.15, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a 1-year low of $135.97 and a 1-year high of $252.88. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The business has a fifty day moving average of $177.57 and a 200-day moving average of $197.47.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.